



Low medication adherence, a major cause of poor outcomes and increased costs, is hard to recognize and manage. TimeStamp's pioneering approach enables the incorporation of IoT into medication providing adherence data into everyday healthcare systems.

Website: www.timestamp.global

COMPANY OVERVIEW

Model: **B2B**

Founded: **2017**

Location: **Israel**

Industries Verticals: **Pharma/ IOT**

Potential Market Size: **\$3.6 Bn by 2023**

Funds raised: **<1M\$**

Company stage: **Pre-revenue**

Commercial stage: **R&D, POC**

PROPOSITION

TimeStamp is adding connectivity & IoT functionality to existing drug-delivery device and packages by applying our proprietary "Smart-Sticker" devices. This pioneering approach enables the incorporation of medication adherence data into everyday healthcare. Unlike competing technologies, TimeStamp's technology, does not depend on patient engagement.

TEAM



Gad Riesenfeld CEO
Experienced senior level executive, former president of Pharmos (NASDAQ) & CEO and Co-Founder of Otic Pharma (NASDAQ & KamaPharm [Kamada])



Ian Solomon CTO
Serial entrepreneur specializing in drug-delivery and diagnostic devices. Co-founder of SteadyMed (NASDAQ)



Amir Elhasid VP BD
30+ years of experience in management roles in the Pharma industry. Global marketing director in Teva and global brand lead for Qvar



Prof. David Price CMO
Professor of Primary Care Respiratory Medicine. His area of interest lies in 'real-life' research, authored over 400 peer-reviewed publications

HIGHLIGHTS

Completed the development of first engineering model and app

3 Patents submitted

Collaboration with a leading pharma company to develop customized solution